• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.

作者信息

Latagliata R, Oliva E N, Volpicelli P, Carmosino I, Breccia M, Vincelli I, Alati C, Napoleone L, Vozella F, Nobile F, Alimena G

机构信息

Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.

出版信息

Acta Haematol. 2008;120(2):104-7. doi: 10.1159/000166864. Epub 2008 Oct 31.

DOI:10.1159/000166864
PMID:18974634
Abstract
摘要

相似文献

1
Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes.每周两次大剂量重组人促红细胞生成素治疗低危骨髓增生异常综合征患者的贫血
Acta Haematol. 2008;120(2):104-7. doi: 10.1159/000166864. Epub 2008 Oct 31.
2
Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.促红细胞生成素联合粒细胞集落刺激因子治疗低危骨髓增生异常综合征贫血优于单用促红细胞生成素：一项单中心随机研究结果
Ann Hematol. 2006 Mar;85(3):174-80. doi: 10.1007/s00277-005-0044-6. Epub 2006 Jan 12.
3
High-dose (40,000 IU twice/week) alpha recombinant human erythropoietin as single agent in low/intermediate risk myelodysplastic syndromes: a retrospective investigation on 133 patients treated in a single institution.高剂量（40000IU，每周两次）α 重组人促红细胞生成素作为单一药物治疗低/中危骨髓增生异常综合征：单中心治疗 133 例患者的回顾性研究。
Am J Hematol. 2011 Sep;86(9):762-7. doi: 10.1002/ajh.22111.
4
[Preliminary results of erythropoietin treatment of anemia in myelodysplastic syndromes and chronic lymphocytic leukemia].[促红细胞生成素治疗骨髓增生异常综合征和慢性淋巴细胞白血病贫血的初步结果]
Pol Tyg Lek. 1996 May;51(19-22):285-8.
5
Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.人重组促红细胞生成素 + 13 - 顺式维甲酸与二羟基化维生素D3联合应用改善低/中危骨髓增生异常综合征中重度贫血的疗效
Br J Haematol. 2009 Feb;144(3):342-9. doi: 10.1111/j.1365-2141.2008.07465.x. Epub 2008 Nov 19.
6
Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.氨磷汀联合促红细胞生成素治疗骨髓增生异常综合征
Haematologica. 2002 Mar;87(3):322-3.
7
A mathematical model for the evaluation of amplitude of hemoglobin fluctuations in elderly anemic patients affected by myelodysplastic syndromes: correlation with quality of life and fatigue.评估骨髓增生异常综合征老年贫血患者血红蛋白波动幅度的数学模型：与生活质量和疲劳的相关性
Leuk Res. 2007 Feb;31(2):249-52. doi: 10.1016/j.leukres.2006.05.015. Epub 2006 Jun 30.
8
Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.
Leuk Res. 2006 Apr;30(4):385-8. doi: 10.1016/j.leukres.2005.08.020. Epub 2005 Oct 10.
9
Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome.骨髓增生异常综合征中心脏重塑和生活质量的血红蛋白水平阈值
Leuk Res. 2005 Oct;29(10):1217-9. doi: 10.1016/j.leukres.2005.03.004. Epub 2005 Apr 7.
10
Treatment of anaemia with rHuEpo in patients with MDS.重组人促红细胞生成素治疗骨髓增生异常综合征患者的贫血
Med Oncol. 1998 Aug;15 Suppl 1:S35-7.

引用本文的文献

1
A Systematic Literature Review of Predictors of Erythropoiesis-Stimulating Agent Failure in Lower-Risk Myelodysplastic Syndromes.低危骨髓增生异常综合征中促红细胞生成素刺激剂失效预测因素的系统文献综述
J Clin Med. 2024 May 4;13(9):2702. doi: 10.3390/jcm13092702.
2
The Clinical Efficacy of Epoetin Alfa and Darbepoetin Alfa in Patients with Low-Risk or Intermediate-1-Risk Myelodysplastic Syndrome: Retrospective Multi-center Real-Life Study.阿法依泊汀和阿法达贝泊汀治疗低危或中危-1骨髓增生异常综合征患者的临床疗效：回顾性多中心真实世界研究
Indian J Hematol Blood Transfus. 2022 Apr;38(2):299-308. doi: 10.1007/s12288-021-01458-1. Epub 2021 Jun 26.
3
Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis.
不同剂量促红细胞生成素治疗骨髓增生异常综合征患者的效果：倾向评分匹配分析。
Cancer Med. 2019 Dec;8(18):7567-7576. doi: 10.1002/cam4.2638. Epub 2019 Oct 27.
4
Treatment of low-risk myelodysplastic syndromes.低危骨髓增生异常综合征的治疗
Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):462-469. doi: 10.1182/asheducation-2016.1.462.
5
Erythropoietin or darbepoetin for patients with cancer.促红细胞生成素或达比泊汀用于癌症患者。
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD003407. doi: 10.1002/14651858.CD003407.pub5.